IBI343

IBI343 is an investigational agent whose form is not stated in the registry developed by Innovent Biologics (Suzhou). Its target is Claudin 18.2 (the sponsor names Claudin 18.2 (CLDN18.2)). ClinicalTrials.gov describes the intervention as: Subjects in the experimental arm will receive IBI343 6mg/kg intravenous infusion (IV) D1, Q3W in 3-week cycle. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, including the phase 3 study NCT07066098 (A Multicenter Study of IBI343 Monotherapy Versus Placebo in Subjects With Previously Treated, Claudin (CLDN) 18.2-positive, Pancreatic Cancer(G-HOPE-002)), in pancreatic ductal adenocarcinoma. The largest, NCT07066098, plans to enrol 201 participants with primary completion expected 2027-06-30. Status reflects the highest phase registered on ClinicalTrials.gov at the 2026-09-11 check; no efficacy results are recorded here.